This episode explores how AI, particularly the concept of “AI scientists,” reshapes drug discovery by accelerating timelines, reducing costs, and boosting early-phase success rates. We examine AI’s growing role in target identification, de novo molecule generation, preclinical property prediction, trial optimization, and drug repurposing. Notably, AI-native companies have reported Phase I success rates up to 90%. Yet, the field faces key challenges: data privacy, algorithmic bias, explainability, and the absence of any AI-discovered drug reaching commercialization. We also discuss the ethical implications of over-automation and emphasize the need for transparency, human oversight, and patient-centered approaches in realizing AI’s full promise. Produced by Dr. Jake Chen.